Allele Biotechnology
A clinical-stage biotechnology company developing mRNA-based cellular reprogramming technologies and 3D-bioprinted human organs for regenerative medicine.
- CEO / Founder
- Jiwu Wang, PhD
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $43.8M
- Latest Round
- ARPA-H Grant (multi-year)
- Key Investors
- Yuan Capital, ARPA-H, NIH, CIRM
Technology & Products
Key Products
Proprietary 'footprint-free' mRNA-based cellular reprogramming technology; high-resolution 3D bioprinting; in-house cGMP manufacturing; iPSC-based cell therapy platform; development of iPSC-derived cell therapies for diabetes and spinal cord injury; mNeonGreen fluorescent protein; 3D bioprinted human organs (e.g., livers).
Technological Advantage
Operates the world's first cGMP-compliant facility dedicated to mRNA-based iPSC production, combining proprietary high-resolution 3D bioprinting with advanced stem cell biology to create vascularized, functional organoids.
Differentiation
Value Proposition
Provides a safer, 'footprint-free' mRNA reprogramming method to create high-quality induced pluripotent stem cells (iPSCs) and functional 3D-printed tissues, bypassing the risks of genomic integration and donor organ shortages.
How They Differentiate
Proprietary 'footprint-free' mRNA-based cellular reprogramming that avoids viral or DNA integration, combined with high-resolution 3D bioprinting and in-house cGMP manufacturing.
Market & Competition
Target Customers
Pharmaceutical and biotech companies, academic research institutions, and eventually healthcare systems/surgeons requiring transplantable tissues.
Industry Verticals
["Regenerative Medicine","Biopharmaceutical Research","Drug Discovery & Toxicity Testing","Cell and Gene Therapy"]
Competitors
Allele Life Sciences, Abbiotec, Zymo Research
Growth & Milestones
Growth Metrics
Transitioned from a reagent supplier to a clinical-stage platform company; secured major federal funding for organ transplant trials.
Major Milestones
["Founded in 1999 as a molecular biology reagent provider.","Patented breakthrough mRNA-based iPSC reprogramming technology in 2011.","Established the world's first cGMP-compliant facility dedicated to mRNA-iPSC production.","Awarded a $25.8M ARPA-H grant in 2025 for the 'LIVER-PRINT' project to develop 3D-printed liver transplants."]
Notable Customers
University of California San Diego (UCSD); Cellular Logistics